O’ConnorKCMcLaughlinKADe JagerPL, et al. Selfantigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med2007; 13: 211–217.
2.
FujiharaK. Neuromyelitis optica spectrum disorders: Still evolving and broadening. Curr Opin Neurol2019; 32: 385–394.
3.
LeiteMASatoDK. MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity – Yes. Mult Scler2020; 26: 272–274.
4.
Cobo-CalvoAMariginierR. MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity—No. Mult Scler2020; 26: 274–276.
5.
SpadaroMGerdesLAKrumbholzM, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2016; 3: e257.
6.
KanekoKSatoDKNakashimaI, et al. CSF cytokine profile in MOG-IgG+neurologic disease is similar to AQP4-IgG+NMOSD but distinct from MS: A cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry2018; 89: 927–936.
7.
WingerchukDMBanwellBBennettJL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology2015; 85: 177–189.
8.
JariusSWilldemannB. Devic’s disease before Devic: On the contribution of Friedrich Albin Schanz (1863−1923). J Neurol Sci2017; 379: 99–102.
9.
GaultF.De la neuromyélite optique aiguë. Thesis, Lyon, 1894.
10.
WingerchukDMHogancampWFO’BrienPC, et al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology1999; 53: 1107–1114.
